Melanoma checkpoint inhibitor detection and treatment
AssigneeOncimmune Germany GmbH
InventorsPetra BUDDE, Peter SCHULZ-KNAPPE, Hans-Dieter ZUCHT
Life of this patent
Estimating the term…
Abstract
Biomarkers are provided for predicting an irAE response associated with administration of anti-CTLA-4 antibodies (i.e. ipilumamb) and antibodies disrupting the PD-1/PD-L1 pathway (i.e. nivolumab or pembrolizumab) for treating melanoma. Methods of treatment incorporating such biomarkers are also provided.
Claims33
A method of identifying a tumor-associated antigen (TAA) for melanoma comprising:
- a) selecting a group of patients with melanoma and a group of patients who are healthy,
- b) assaying the level of an autoantibody to an antigen in a sample from a patient in the group,
- c) comparing the level of the autoantibody from the patient in the group or the group of patients with melanoma to the level of the autoantibody in the group of healthy patients, and
- d) determining that the antigen is a TAA for melanoma if the level of the autoantibody to the antigen is statistically different between the group of patients with melanoma versus the group of healthy patients.
A method of identifying a tumor-associated antigen (TAA) as a marker for melanoma overall survival (MOS) or melanoma disease control rate (MDCR) comprising:
- a) selecting a first group of patients with melanoma who have statistically greater MOS or MDCR than a second group of patients with melanoma,
- b) assaying the level of an autoantibody to the antigen in a sample from each of the patients in the first group,
- c) comparing the level of the autoantibody to the antigen in each of the patients in the first group to the level of the autoantibody in each of the patients in the second group, and
- d) determining that the antigen is a TAA marker for MOS or MDCR if the level of the autoantibody to the antigen is statistically different between the first group of patients and the second group of patients.
A method of identifying and treating a melanoma patient susceptible to an immune-related adverse event (irAE) after treatment with a checkpoint inhibitor comprising:
- a) determining the level of one or more antigens encoded by a gene listed in Table 4 having a positive value for SAM Fold.Change,
- b) assaying the level of one or more antigens in a sample from a melanoma patient,
- c) comparing the level of the one or more antigens with an average level of the one or more antigens for a group of patients with melanoma, and
- d) administering the checkpoint inhibitor to the melanoma patient if (a) the level of the one or more antigens encoded by a gene listed in Table 4 having a value for SAM Fold.Change>1 in the patient is less than the average level of the one or more antigens encoded by a gene listed in Table 4 having a value for SAM Fold.Change>1 in the group of patients with melanoma or (b) the level of the one or more antigens encoded by a gene listed in Table 4 having a value for SAM Fold.Change<=1 in the patient is greater than the average level of the one or more antigens encoded by a gene listed in Table 4 having a value for SAM Fold.Change<=1 in the group of patients with melanoma.
14-22. (canceled)
A method of identifying and treating a melanoma patient with a checkpoint inhibitor comprising:
- a) determining the level of one or more antigens encoded by a gene listed in Table 5 having a value for SAMR Fold.Change>1,
- b) comparing the level of the one or more antigens with an average level of the one or more antigens for a group of patients with melanoma, and
- c) administering the checkpoint inhibitor if the level of the one or more antigens in the patient is greater than the average level of the one or more antigens in the group of patients with melanoma.
24-32. (canceled)
A method of identifying and treating a melanoma patient with Ipilimumab comprising:
- a) determining the level of one or more antigens encoded by a gene listed in Table 6 having a value for SAMR Fold.Change>1,
- b) comparing the level of the one or more antigens with an average level of the one or more antigens for a group of patients with melanoma, and
- c) administering the Ipilimumab if the level of the one or more antigens in the patient is less than the average level of the one or more antigens in the group of patients with melanoma.
A method of identifying and treating a melanoma patient with Ipilimumab comprising:
- a) determining the level of one or more antigens encoded by a gene listed in Table 6 having a value for SAMR Fold.Change<=1,
- b) comparing the level of the one or more antigens with an average level of the one or more antigens for a group of patients with melanoma, and
- c) administering the Ipilimumab if the level of the one or more antigens in the patient is greater than the average level of the one or more antigens in the group of patients with melanoma.
35-39. (canceled)
A method of identifying and treating a melanoma patient with a CTLA-4 inhibitor comprising:
- a) determining the level of one or more antigens encoded by a gene listed in Table 6 having a value for SAMR Fold.Change>1,
- b) comparing the level of the one or more antigens with an average level of the one or more antigens for a group of patients with melanoma, and
- c) administering the CTLA-4 inhibitor if the level of the one or more antigens in the patient is less than the average level of the one or more antigens in the group of patients with melanoma.
A method of identifying and treating a melanoma patient with a CTLA-4 inhibitor comprising:
- a) determining the level of one or more antigens encoded by a gene listed in Table 6 having a value for SAMR Fold.Change<=1,
- b) comparing the level of the one or more antigens with an average level of the one or more antigens for a group of patients with melanoma, and
- c) administering the CTLA-4 inhibitor if the level of the one or more antigens in the patient is greater than the average level of the one or more antigens in the group of patients with melanoma.
42-46. (canceled)
A method of identifying and treating a melanoma patient with a PD-1/PD-L1 pathway inhibitor comprising:
- a) determining the level of one or more antigens encoded by a gene listed in Table 7 having a value for SAMR Fold.Change>1,
- b) comparing the level of the one or more antigens with an average level of the one or more antigens for a group of patients with melanoma, and
- c) administering the PD-1/PD-L1 pathway inhibitor if the level of the one or more antigens in the patient is greater than the average level of the one or more antigens in the group of patients with melanoma.
48-54. (canceled)
A method of identifying and treating a melanoma patient with pembrolizumab comprising:
- a) determining the level of one or more antigens encoded by a gene listed in Table 8 having a value for SAMR Fold.Change<=1,
- b) comparing the level of the one or more antigens with an average level of the one or more antigens for a group of patients with melanoma, and
- c) administering the pembrolizumab if the level of the one or more antigens in the patient is greater than the average level of the one or more antigens in the group of patients with melanoma.
A method of identifying and treating a melanoma patient with pembrolizumab comprising:
- a) determining the level of one or more antigens encoded by a gene listed in Table 8 having a value for SAMR Fold.Change>1,
- b) comparing the level of the one or more antigens with an average level of the one or more antigens for a group of patients with melanoma, and
- c) administering the pembrolizumab if the level of the one or more antigens in the patient is less than the average level of the one or more antigens in the group of patients with melanoma.
57-61. (canceled)
A method of identifying an antigen predictive of development of an irAE or colitis in a patient with melanoma who is treated with a checkpoint inhibitor comprising:
- a) selecting a first group of patients with melanoma who developed irAE or colitis after treatment with the checkpoint inhibitor,
- b) assaying the level of an autoantibody to an antigen in a sample from a patient in the first group who developed irAE or colitis,
- c) comparing the level of the autoantibody from the patient in the first group to the level of the autoantibody in a second group of patients with melanoma after treatment with the checkpoint inhibitor but did not develop irAE or colitis, and
- d) determining that the antigen is predictive of development of an irAE or colitis if the level of the autoantibody to the antigen is statistically different between the first group of patients and the second group of patients.
63-66. (canceled)
A method of identifying an antigen predictive of development of colitis in a patient with melanoma who is treated with a checkpoint inhibitor comprising:
- a) selecting a first group of patients with melanoma who developed colitis after treatment with the checkpoint inhibitor,
- b) assaying the level of an autoantibody to an antigen in a sample from a patient in the first group who developed colitis,
- c) comparing the level of the autoantibody from the patient in the first group to the level of the autoantibody in a second group of patients with melanoma after treatment with the checkpoint inhibitor but did not develop colitis, and
- d) determining that the antigen is predictive of development of colitis if the level of the autoantibody to the antigen is statistically different between the first group of patients and the second group of patients.
68-78. (canceled)
A method of identifying an antigen predictive of development of an irAE in a patient with melanoma who is treated with a checkpoint inhibitor comprising:
- a) selecting a first group of patients with melanoma who developed irAE after treatment with the checkpoint inhibitor,
- b) assaying the level of an autoantibody to an antigen in a sample from a patient in the first group who developed the irAE,
- c) comparing the level of the autoantibody from the patient in the first group to the level of the autoantibody in a second group of patients with melanoma after treatment with the checkpoint inhibitor but did not develop the irAE, and
- d) determining that the antigen is predictive of development of the irAE if the level of the autoantibody to the antigen is statistically different between the first group of patients and the second group of patients.
80-85. (canceled)
Dependencies are inferred from the claim text.